Literature DB >> 22656887

Deficiency of the CGRP receptor component RAMP1 attenuates immunosuppression during the early phase of septic peritonitis.

Gabriela Jusek1, Daniel Reim, Kazutake Tsujikawa, Bernhard Holzmann.   

Abstract

The neuropeptide CGRP contributes to the control of excessive cytokine production in endotoxemia models. However, the function of CGRP in sepsis caused by infection with viable pathogens is unknown. Here, we show that mice deficient for the CGRP receptor component RAMP1 have an improved anti-bacterial defense during the early, but not late, phase of polymicrobial septic peritonitis. The protective effect of Ramp1-deficiency was associated with reduced levels of IL-10 in plasma and peritoneal lavage fluid. Consistent with these findings, CGRP markedly increased IL-10 production of peritoneal and bone marrow-derived macrophages in response to short term stimulation with LPS in vitro. In addition, the lack of an intact CGRP receptor resulted in an increased recruitment and activation of neutrophils and caused an enhanced release of defensin-α1 in the peritoneal cavity. Considered together, our results identify the neuropeptide CGRP as a crucial immunosuppressive mediator impairing host defense during the early, but not late, phase of septic peritonitis.
Copyright © 2012 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22656887     DOI: 10.1016/j.imbio.2012.04.009

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  10 in total

Review 1.  Crosstalk between the nociceptive and immune systems in host defence and disease.

Authors:  Stephen B McMahon; Federica La Russa; David L H Bennett
Journal:  Nat Rev Neurosci       Date:  2015-07       Impact factor: 34.870

Review 2.  Receptor Activity-Modifying Proteins (RAMPs): New Insights and Roles.

Authors:  Debbie L Hay; Augen A Pioszak
Journal:  Annu Rev Pharmacol Toxicol       Date:  2015-10-23       Impact factor: 13.820

Review 3.  Nociceptor Sensory Neuron-Immune Interactions in Pain and Inflammation.

Authors:  Felipe A Pinho-Ribeiro; Waldiceu A Verri; Isaac M Chiu
Journal:  Trends Immunol       Date:  2016-10-25       Impact factor: 16.687

4.  Calcitonin Gene-Related Peptide Negatively Regulates Alarmin-Driven Type 2 Innate Lymphoid Cell Responses.

Authors:  Antonia Wallrapp; Patrick R Burkett; Samantha J Riesenfeld; Se-Jin Kim; Elena Christian; Raja-Elie E Abdulnour; Pratiksha I Thakore; Alexandra Schnell; Conner Lambden; Rebecca H Herbst; Pavana Khan; Kazutake Tsujikawa; Ramnik J Xavier; Isaac M Chiu; Bruce D Levy; Aviv Regev; Vijay K Kuchroo
Journal:  Immunity       Date:  2019-10-08       Impact factor: 31.745

5.  Cross-talk between neural and immune receptors provides a potential mechanism of homeostatic regulation in the gut mucosa.

Authors:  B M Assas; J A Miyan; J L Pennock
Journal:  Mucosal Immunol       Date:  2014-09-03       Impact factor: 7.313

Review 6.  Calcitonin gene-related peptide: physiology and pathophysiology.

Authors:  F A Russell; R King; S-J Smillie; X Kodji; S D Brain
Journal:  Physiol Rev       Date:  2014-10       Impact factor: 37.312

7.  Nephrilin peptide modulates a neuroimmune stress response in rodent models of burn trauma and sepsis.

Authors:  Desmond D Mascarenhas; Amina Elayadi; Baljit K Singh; Anesh Prasai; Sachin D Hegde; David N Herndon; Celeste C Finnerty
Journal:  Int J Burns Trauma       Date:  2013-11-01

Review 8.  Pain and immunity: implications for host defence.

Authors:  Pankaj Baral; Swalpa Udit; Isaac M Chiu
Journal:  Nat Rev Immunol       Date:  2019-07       Impact factor: 53.106

9.  Comparison of Treatment Effects of Different Iron Chelators in Experimental Models of Sepsis.

Authors:  Christian Lehmann; Maral Aali; Juan Zhou; Bruce Holbein
Journal:  Life (Basel)       Date:  2021-01-14

Review 10.  Calcitonin gene-related peptide is a key neurotransmitter in the neuro-immune axis.

Authors:  Bakri M Assas; Joanne I Pennock; Jaleel A Miyan
Journal:  Front Neurosci       Date:  2014-02-14       Impact factor: 4.677

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.